Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Annexon Inc (ANNX)

Annexon Inc (ANNX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Annexon to Present at the 25th Annual Needham Virtual Healthcare Conference GlobeNewswire - Wed Apr 8, 3:05PM CDT

BRISBANE, Calif., April 08, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory...

ANNX : 5.81 (-0.68%)
Annexon Reports Fourth Quarter and Year-End 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones GlobeNewswire - Mon Mar 30, 3:01PM CDT

ARCHER II Topline Pivotal Phase 3 Data in Geographic Atrophy (GA) Expected Q4 2026; Vonaprument has Potential to Be the First Vision-Preserving Therapy for GA Tanruprubart MAA Filed in Europe with...

ANNX : 5.81 (-0.68%)
Annexon Has Been Quietly Building Toward This Moment. Investors Are About to Find Out If It Was Enough. Barchart - Sun Mar 29, 4:00PM CDT

Barchart Research What to Expect from ANNX Earnings ANNX Generated March 27, 2026 Current Price $5.00 EPS Estimate $-0.32 Consensus Rating Strong Buy Average Move 5.49% Annexon Has Been Quietly Building...

ANNX : 5.81 (-0.68%)
Annexon Has Been Quietly Building Toward This Moment. Investors Are About to Find Out If It Was Enough. Barchart - Sat Mar 28, 4:01PM CDT

Barchart Research What to Expect from ANNX Earnings ANNX Generated March 27, 2026 Current Price $5.00 EPS Estimate $-0.32 Consensus Rating Strong Buy Average Move 5.49% Annexon Has Been Quietly Building...

ANNX : 5.81 (-0.68%)
Annexon Has Been Quietly Building Toward This Moment. Investors Are About to Find Out If It Was Enough. Barchart - Fri Mar 27, 4:02PM CDT

Barchart Research What to Expect from ANNX Earnings ANNX Generated March 27, 2026 Current Price $5.00 EPS Estimate $-0.32 Consensus Rating Strong Buy Average Move 5.49% Annexon Has Been Quietly Building...

ANNX : 5.81 (-0.68%)
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire - Mon Mar 16, 3:05PM CDT

BRISBANE, Calif., March 16, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory...

ANNX : 5.81 (-0.68%)
Annexon Biosciences to Present at the TD Cowen 46th Annual Health Care Conference GlobeNewswire - Tue Feb 24, 7:00AM CST

BRISBANE, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory...

ANNX : 5.81 (-0.68%)
Annexon to Host In-Person and Virtual KOL Event to Discuss Vonaprument for the Treatment of Geographic Atrophy GlobeNewswire - Tue Feb 17, 7:00AM CST

BRISBANE, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory...

ANNX : 5.81 (-0.68%)
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire - Fri Jan 16, 4:05PM CST

BRISBANE, Calif., Jan. 16, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory...

ANNX : 5.81 (-0.68%)
Annexon Accelerating Next Generation Targeted Immunotherapy Platform for Treatment of Neuroinflammatory Diseases with Multiple Registrational Milestones in 2026 GlobeNewswire - Mon Jan 12, 6:00AM CST

Tanruprubart MAA Filed with Potential to Be the First Targeted Fast-Acting Therapy for  Guillain-Barré Syndrome ( GBS); BLA Submission with U.S./European Data Planned in 2026 Vonaprument Pivotal...

ANNX : 5.81 (-0.68%)

Barchart Exclusives

Ignore the Anthropic Panic and Keep Buying Palantir Stock, Says Wedbush Barchart - Mon Apr 13, 3:53PM CDT
Wedbush urges investors to tune out the Anthropic noise and keep buying Palantir, betting on its strong AI moat and solid fundamentals. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.